Biogen Increases Profit Potential on Investigational Alzheimer’s Disease Treatment Aducanumab Through Amended Agreement with Neurimmune Holding AG

Biogen (NASDAQ: BIIB) announced that it has increased the profit potential on aducanumab, its Phase 3 investigational treatment for early Alzheimer’s disease, by reducing the potential royalty payment on potential commercial sales of aducanumab to Neurimmune Holding AG. In exchange for a 15 percent reduction in the previously negotiated royalty rates, Biogen agreed to make a one-time $150 million payment to Neurimmune Holding AG.

• Source: media.biogen
• 473
• October 27, 2017